Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
J A
JA
O'Shaughnessy
D000284:Administration, Oral; D000368:Aged; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000175:diagnosis*; D007677:Kidney Function Tests; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome
D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil